Pregnancy-Related Changes in Zonisamide and Oxcarbazepine Clearance
Abstract number :
3.244
Submission category :
4. Clinical Epilepsy / 4E. Women's Issues
Year :
2019
Submission ID :
2422142
Source :
www.aesnet.org
Presentation date :
12/9/2019 1:55:12 PM
Published date :
Nov 25, 2019, 12:14 PM
Authors :
Torri Lee, Brigham and Women's Hospital; P. Emanuela E. Voinescu, Brigham and Women's Hospital; Thomas F. McElrath, Brigham and Women's Hospital/ Harvard Medical School; Stephanie Allien, Brigham and Women's Hospital; Kathleen Tang, Harvard School of Publ
Rationale: Oxcarbazepine (OXC) and zonisamide (ZNS) have growing evidence for low risk of major congenital malformation and are considered by many experts as next in line for use in women with epilepsy (WWE) of childbearing age after levetiracetam (LEV) and lamotrigine (LTG). There is solid evidence for pregnancy-related pharmacokinetic changes for LTG and LEV, and increased risk for seizure worsening with serum concentrations <
Clinical Epilepsy